SANOFI-AVENTIS (EPA:SAN) Press Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy
Transparency directive : regulatory news
15/05/2022 09:30
SANOFI-AVENTIS's latest news
17/04/2024 07:00
12/04/2024 20:05
22/03/2024 07:30
15/03/2024 20:04
24/02/2024 15:51
23/02/2024 18:45
23/02/2024 07:00
22/02/2024 19:02
20/02/2024 23:40
15/02/2024 14:00
Other stories
23/04/2024 11:37
23/04/2024 17:49
23/04/2024 16:27
23/04/2024 10:04
23/04/2024 17:51
23/04/2024 16:00
23/04/2024 15:06
23/04/2024 16:55
23/04/2024 14:22
23/04/2024 16:46
23/04/2024 17:30
23/04/2024 10:23
23/04/2024 12:29
23/04/2024 12:41
23/04/2024 11:11
23/04/2024 14:59
23/04/2024 16:51
23/04/2024 12:50
23/04/2024 15:00
23/04/2024 11:00
23/04/2024 12:51
23/04/2024 14:16
23/04/2024 14:07
23/04/2024 14:34
23/04/2024 08:57
23/04/2024 12:08
23/04/2024 16:30
23/04/2024 10:36
23/04/2024 17:56
23/04/2024 12:32
23/04/2024 16:59
22/04/2024 18:16
22/04/2024 17:52
23/04/2024 09:41
23/04/2024 09:00
23/04/2024 12:06
23/04/2024 12:37
22/04/2024 07:45